CN120324434A - 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌 - Google Patents

使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌

Info

Publication number
CN120324434A
CN120324434A CN202510482379.2A CN202510482379A CN120324434A CN 120324434 A CN120324434 A CN 120324434A CN 202510482379 A CN202510482379 A CN 202510482379A CN 120324434 A CN120324434 A CN 120324434A
Authority
CN
China
Prior art keywords
patient
combination therapy
gdc
palbociclib
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510482379.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·O’H·劳克勒
S·米兰
M·C·斯密特
M·C·格林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN120324434A publication Critical patent/CN120324434A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202510482379.2A 2020-05-12 2021-05-10 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌 Pending CN120324434A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063023501P 2020-05-12 2020-05-12
US63/023,501 2020-05-12
PCT/US2021/031491 WO2021231250A1 (en) 2020-05-12 2021-05-10 Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
CN202180034978.8A CN115551513B (zh) 2020-05-12 2021-05-10 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180034978.8A Division CN115551513B (zh) 2020-05-12 2021-05-10 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌

Publications (1)

Publication Number Publication Date
CN120324434A true CN120324434A (zh) 2025-07-18

Family

ID=76250442

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510482379.2A Pending CN120324434A (zh) 2020-05-12 2021-05-10 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌
CN202180034978.8A Active CN115551513B (zh) 2020-05-12 2021-05-10 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180034978.8A Active CN115551513B (zh) 2020-05-12 2021-05-10 使用包含gdc-9545和cdk4/6抑制剂的组合疗法治疗乳腺癌

Country Status (11)

Country Link
US (2) US11918561B2 (cg-RX-API-DMAC7.html)
EP (1) EP4149476A1 (cg-RX-API-DMAC7.html)
JP (3) JP2023500558A (cg-RX-API-DMAC7.html)
KR (1) KR20230009390A (cg-RX-API-DMAC7.html)
CN (2) CN120324434A (cg-RX-API-DMAC7.html)
AU (2) AU2021272100B2 (cg-RX-API-DMAC7.html)
CA (1) CA3182018A1 (cg-RX-API-DMAC7.html)
IL (1) IL298071A (cg-RX-API-DMAC7.html)
MX (1) MX2022014133A (cg-RX-API-DMAC7.html)
TW (1) TWI800827B (cg-RX-API-DMAC7.html)
WO (1) WO2021231250A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7846700B2 (ja) * 2021-02-16 2026-04-15 ジェネンテック, インコーポレイテッド Gdc-9545とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療
TW202400230A (zh) * 2022-03-14 2024-01-01 美商建南德克公司 乳癌的組合療法
CN121337802B (zh) * 2025-10-23 2026-04-14 安徽益普克医药科技发展有限公司 一种雌激素降解剂衍生物及其制备方法与用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4772247A2 (en) * 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
KR102358935B1 (ko) * 2014-02-12 2022-02-04 가부시키가이샤 한도오따이 에네루기 켄큐쇼 전자 기기
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
MX384605B (es) 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
WO2017160990A1 (en) 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
LT3810283T (lt) * 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
AU2019321588C1 (en) 2018-08-17 2026-05-14 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
JP7826068B2 (ja) * 2022-03-11 2026-03-09 本田技研工業株式会社 パワーユニット、及びパワーユニットを搭載した作業機

Also Published As

Publication number Publication date
US20240173306A1 (en) 2024-05-30
US11918561B2 (en) 2024-03-05
AU2021272100B2 (en) 2024-09-12
EP4149476A1 (en) 2023-03-22
AU2024202832B2 (en) 2026-04-30
JP2023500558A (ja) 2023-01-10
KR20230009390A (ko) 2023-01-17
US12303495B2 (en) 2025-05-20
IL298071A (en) 2023-01-01
AU2021272100A1 (en) 2022-11-17
US20210353601A1 (en) 2021-11-18
MX2022014133A (es) 2022-11-30
CN115551513B (zh) 2025-05-02
AU2024202832A1 (en) 2024-05-23
TWI800827B (zh) 2023-05-01
CN115551513A (zh) 2022-12-30
CA3182018A1 (en) 2021-11-18
WO2021231250A1 (en) 2021-11-18
JP2024102045A (ja) 2024-07-30
TW202203913A (zh) 2022-02-01
JP2023175688A (ja) 2023-12-12

Similar Documents

Publication Publication Date Title
US12303495B2 (en) Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor
JP7667132B2 (ja) Atp競合性akt阻害剤、cdk4/6阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置
US20260041695A1 (en) Combination therapies for treatment of breast cancer
JP7846700B2 (ja) Gdc-9545とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療
HK40084792A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
HK40129153A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
HK40084792B (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
HK40098151A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib
HK40066922A (en) Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40129153

Country of ref document: HK